Ugandan student Hakim Nakaana Kakooza was among 14 students from the African Leadership University (ALU) who participated in the fourth annual Silicon Valley Global Leadership Programme -- a ...

On Wednesday, ALX Oncology Holdings Inc. reported the outcomes of its Annual Meeting of stockholders, which took place on June 11, 2025. The micro-cap pharmaceutical company, currently valued at ...

S&P 500 futures are down 0.3%. Dow Jones Industrial Average futures are slipping 0.3%. Nasdaq 100 futures are falling 0.4%. On Wednesday, the Dow Jones Industrial Average fell 1 points, or 0%, to ...

ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025.

Scott McLaughlin’s Indianapolis 500 was finished before the race went green. McLaughlin and the rest of the field were doing pace laps to get ready for the green flag.

Alexander's (ALX) delivered FFO and revenue surprises of 13.73% and 1.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

ALX Nigeria has unveiled Creative Tech Lite, a new initiative designed to equip the continent’s creators with in-demand digital skills. Touted as a game-changer for Africa’s creative economy ...

ALX Oncology Holdings Inc., a pharmaceutical company based in South San Francisco, California, has been notified of its non-compliance with a Nasdaq listing requirement. On April 23, 2025, the ...

ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025.

--ALX Oncology Holdings Inc.,, a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced receipt of U.S ...